Skip to content
This is a text only leaflet, designed for the visually impaired. Please visit our electronic Medicines Compendium (eMC) website to view the original document which may contain images or tables.

You may be able to get this leaflet in large print, Braille or as an audio CD, call the RNIB Medicine Leaflet line on 0800 198 5000 for more information.

The product code for this leaflet is: PL 04425/0158

 

Telfast 180mg film-coated tablets

Company Details

SANOFI


1 Onslow StreetGuildfordSurreyGU1 4YS
Telephone:
Fax:
Medical Information Direct Line:
Medical Information e-mail:uk-medicalinformation@sanofi.com
[view all information leaflets from this company]

PATIENT INFORMATION LEAFLET

TELFAST 180 mg film-coated tablets

Fexofenadine hydrochloride

Is this leaflet hard to see or read?

In the UK Phone 0845 372 7101 for help

In Ireland Phone 01 403 5600 for help

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Telfast is and what it is used for
2. What you need to know before you take Telfast
3. How to take Telfast
4. Possible side effects
5. How to store Telfast
6. Contents of the pack and other information

Go to top of the page

1. What Telfast is and what it is used for

Telfast contains fexofenadine hydrochloride, which is an antihistamine.

Telfast 180 mg is used in adults and adolescents of 12 years and older to relieve the symptoms that occur with long term allergic skin reactions (chronic idiopathic urticaria) such as itching, swelling and rashes.

Go to top of the page

2. What you need to know before you take Telfast

Do not take Telfast

  • if you are allergic to fexofenadine or any of the other ingredients of this medicine (listed in section 6)

Warnings and precautions

Talk to your doctor or pharmacist before taking Telfast if:

  • you have problems with your liver or kidneys
  • you have or ever had heart disease, since this kind of medicine may lead to a fast or irregular heart beat
  • you are elderly

If any of these apply to you, or if you are not sure, tell your doctor before taking Telfast.

Other medicines and Telfast

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Indigestion remedies containing aluminium and magnesium may affect the action of Telfast by lowering the amount of medicinal product absorbed.

It is recommended that you leave about 2 hours between the time that you take Telfast and your indigestion remedy.

Pregnancy and breast-feeding

Ask your doctor or pharmacist for advice before taking any medicine.

Do not take Telfast if you are pregnant, unless necessary.

Telfast is not recommended during breast-feeding.

Driving and using machines

Telfast is unlikely to affect your ability to drive or operate machinery. However, you should check that these tablets do not make you feel sleepy or dizzy before driving or operating machinery.

Go to top of the page

3. How to take Telfast

Always take this medicine exactly as your doctor has told you.

Check with your doctor or pharmacist if you are not sure.

For adults and children aged 12 years and over

The recommended dose is one tablet (180 mg) daily.

Take your tablet with water before a meal.

If you take more Telfast than you should

If you take too many tablets, contact your doctor or the nearest hospital emergency department immediately.

Symptoms of an overdose in adults are dizziness, drowsiness, fatigue and dry mouth.

If you forget to take Telfast

Do not take a double dose to make up for a forgotten tablet.

Take the next dose at the usual time as prescribed by your doctor.

If you stop taking Telfast

Tell your doctor if you want to stop taking Telfast before you have finished your course of treatment.

If you stop taking Telfast earlier than planned, your symptoms may return.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Go to top of the page

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor immediately and stop taking Telfast if you experience:

  • swelling of the face, lips, tongue or throat and difficulty breathing, as these may be signs of a serious allergic reaction.

Common side effects (may affect up to 1 in 10 people):

  • headache
  • drowsiness
  • feeling sick (nausea)
  • dizziness.

Uncommon side effects (may affect up to 1 in 100 people):

  • tiredness
  • sleepiness.

Additional side effects (frequency not known: cannot be estimated from the available data) which may occur are:

  • difficulty sleeping (insomnia)
  • sleeping disorders
  • bad dreams
  • nervousness
  • fast or irregular heart beat
  • diarrhoea
  • skin rash and itching
  • hives
  • serious allergic reactions which can cause swelling of the face, lips, tongue or throat, flushing, chest tightness, and difficulty breathing.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

UK:

You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard

Ireland:

Reports may be made by following the links to the online reporting option accessible from the IMB homepage, or by completing the downloadable report form also accessible from the IMB website, which may be completed manually and submitted to the IMB via freepost, to the following address:

FREEPOST
Pharmacovigilance Section
Irish Medicines Board
Kevin O’Malley House
Earlsfort Centre
Earlsfort Terrace
Dublin 2
Tel:+353 1 6764971
Fax:+353 1 6762517
Website:www.imb.ie
e-mail:imbpharmacovigilance@imb.ie

Malta:

ADR Reporting
The Medicines Authority
Post-Licensing Directorate
203 Level 3
Rue D'Argens
GŻR-1368 Gżira
Website:www.medicinesauthority.gov.mt
e-mail:postlicensing.medicinesauthority@gov.mt

By reporting side effects you can help provide more information on the safety of this medicine.

Go to top of the page

5. How to store Telfast

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage condition.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Go to top of the page

6. Contents of the pack and other information

What Telfast 180 mg contains

  • The active substance is fexofenadine hydrochloride. Each tablet contains 180 mg of fexofenadine hydrochloride.
  • The other ingredients are:
    • Tablet core: microcrystalline cellulose, pregelatinised maize starch, croscarmellose sodium, magnesium stearate.
    • Film coating: hypromellose, povidone, titanium dioxide (E171), colloidal anhydrous silica, macrogol 400 and iron oxide (E172).

What Telfast 180 mg looks like and contents of the pack

Telfast 180 mg film-coated tablets are peach coloured, capsule shaped tablets marked with “018” on one side and a scripted “e” on the other.

Telfast is presented in blister packs. Each tablet is blistered.

Telfast is available in packs of 2 (sample only), 10, 15, 20, 30, 50, 100 and 200 (as 10x20) tablets per package.

Not all pack sizes are marketed.

Marketing Authorisation Holder:

In the UK:

Sanofi
One Onslow Street
Guildford
Surrey
GU1 4YS
UK
Tel:0845 372 7101
email: uk-medicalinformation@sanofi.com

Manufacturer

Sanofi Winthrop industrie
30-36 Avenue Gustave Eiffel
37100 Tours
France

This medicinal product is authorised in the Member States of the EEA under the following names:

Belgium: Telfast 180 mg filmomhulde tabletten

Denmark: Telfast, filmovertrukne tabletter 180 mg

Finland: Telfast 180 mg tabletti, kalvopäällysteinen

Germany: Telfast 180 mg

Ireland: Telfast 180 mg film coated tablets

Italy: Telfast 180 mg compresse rivestite con film

Luxembourg: Telfast 180 mg filmomhulde tabletten

Portugal: Telfast 180, comprimidos revestidos por película

Spain: Fexofenadina Sanofi 180 mg comprimidos recubiertos con película

Sweden: Telfast 180 mg filmdragerade tabletter

United Kingdom: Telfast 180 mg film coated tablets

Go to top of the page

This leaflet was last revised in 04/2014

554825


Text size normal Text size at 110% Text size at 120%

CHANGE FORMAT

 

USEFUL INFO

 

QUICK LINKS